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a b s t r a c t
Aim: This perspective paper provides an overview of several key tensions and challenges
within the social context of neuromodulation, and it suggests a means of securing the
future of paediatric neuromodulation in light of these.
Results: Tensions and challenges relate to: the considerable clinical and economic need for
new therapies to manage neurological diseases; significant commercial involvement in the
field; funding pressures; public perceptions (particularly unrealistic expectations); and the
emerging Responsible Research and Innovation initiative. This paper argues that managing
these challenges and tensions requires that clinicians working within the field adopt what
could be called a broad clinical gaze. This paper will define the broad clinical gaze, and it will
propose several ways in which a broad clinical gaze can be e and indeed is being e
operationalised in recent advances in neuromodulation in children. These include the use
of multidisciplinary and interdisciplinary clinical team structures, the adoption of clinical
assessment tools that capture day-to-day functionality, and the use of patient registries.
Conclusion: By adopting a broad clinical gaze, clinicians and investigators can ensure that
the field as a whole can responsibly and ethically deliver on its significant clinical potential.
© 2016 The Author(s). Published by Elsevier Ltd on behalf of European Paediatric Neurology
Society. This is an open access article under the CC BY license (http://creativecommons.
org/licenses/by/4.0/).
1. Introduction
The emerging area of paediatric neuromodulation represents
an exciting and highly promising set of developments in the
management of neurological illness in children. However as
with many emerging, innovative clinical developments, its
potential may be hindered by challenges in the wider social
and political context of healthcare research and provision. It is
therefore necessary that clinicians and investigators within
the area of paediatric neuromodulation are attentive to such
challenges, and that they collaboratively establish a set of
responsible practices for mitigating them. The work of the
Irving Cooper (1922e1985) serves as a useful introductory
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illustration as to why this is important. Cooper was a pioneer
in functional neurosurgery, developing several novel tech-
niques for managing movement disorders and epilepsy: a
cryosurgical probe to conduct thalamectomy,1 cerebellum
stimulation to manage spasticity and cerebral palsy,2e4 and
deep brain stimulation (DBS) of the thalamus or internal
capsule to manage tremor, spasticity, and dystonia.3,5,6 These
techniques, Cooper claimed, delivered meaningful improve-
ments to patients. Yet during his time and until this day, his
work has been treated with a mixture of admiration and
scepticism. He clearly made important contributions to un-
derstandings of movement disorders and neuromodulation,
but because of what has been described as his poor research
technique and his inclination for working within his own,
isolated “investigative domain”, the true clinical implications
of his techniques cannot be elucidated.7 At that time, many of
the standardmovement disorder clinical assessment tools did
not exist, and Cooper tended to rely on his own subjective
measures for capturing clinical outcomes. Much of his work
was published in the form of anecdotal reports rather than as
part of a scientific series. Because of this, a valuable oppor-
tunity to produce a useful body of data on neuromodulation
was missed, and the field as a whole was deprived of some
much needed-direction.
Since Cooper's time the field of neuromodulation has been
assisted by various technological developments (most mark-
edly in imaging technology) accompanied by major advance-
ments in understandings of neuro-networks, particularly in
basal ganglia function (e.g.8). Clinicians now also have access
to standardised, validated tools for rating disease severity and
assessing clinical outcomes that enable a common language
between clinical centres and the pooling of data. The field,
then, is on much firmer ground that it was in Cooper's time. It
is important, however, not to become complacent about these
scientific and technical developments and assume they will
assure that neuromodulation will live up to its considerable
potential. Now more than ever it is vital that clinicians and
investigators collaboratively establish a set of responsible
practices for the field. There are, as this paper will explain,
various contextual social, economic, and institutional factors
that could hinder the field, and which pose significant chal-
lenges for biomedical innovation more generally. These relate
to the commercial climate and public perceptions, pressure on
national healthcare budgets, and the European Commission's
call for Responsible Research and Innovation (RRI). These
factors should not be considered secondary to the scientific
and clinical challenges of translational medicine e they are
challenges that need to be addressed and managed at all
stages of the innovation process.
This paper will provide an overview of these challenges,
and in doing so, it will suggest thatmanaging these challenges
will require that investigators and clinicians perceive disease
as biopsychosocial phenomenon, and it will require capturing
and evaluating the social impact of disease, and of the inter-
vention. It will require, in other words, that investigators and
clinicians deploy what could be called a broad clinical gaze.
Drawing on the French philosopher Michel Foucault's notion
of the Medical gaze, this paper will define the broad clinical
gaze, and it will propose several ways in which a broad clinical
gaze can be e and indeed is being e operationalised in recent
advances in neuromodulation (some of which feature in this
special issue). These include the use of multidisciplinary and
interdisciplinary clinical team structures, the adoption of
clinical assessment tools that capture day-to-day function-
ality, and the use of patient registries. Such measures, it is
argued, can help with the production of a pool of valuable
evidence on the clinical effectiveness and social impact of
neuromodulation, and they can help ensure that innovation
within the field is directed towards genuine social and clinical
need. This paper will also highlight some of the institutional
constraints that can hinder the ability to operationalise a
broad clinical gaze. Overcoming such constraints will require
coordinated action within field, and this paper will conclude
by suggesting that such coordinated action can be seen as
moulding an institutional context that embodies responsible
research and innovation and will enable neuromodulation to
deliver on its considerable clinical potential.
2. The social context of neuromodulation:
key challenges and tensions
First and foremost, the social context of the field is charac-
terised by a considerable and urgent need for therapies for
managing neurological diseases in children. Neurological
disease is a cause of great suffering for patients, and is often a
huge burden for families and carers. For this reason, the
Nuffield Council on Bioethics (an influential ‘think tank’ in the
UK) has stated that society has a moral obligation e in
accordance with the ethical principle of beneficence e to
explore and develop new therapeutic interventions, and they
explicitly identify neuromodulation as a promising field in
this regard.9 Additionally, neurological illness also constitutes
a huge economic burden for nation-states. According to one
estimate, the total economic cost of brain disorders (which
includes bothmental and neurological disorders) in Europe for
2010 was 798 billion EUR; a figure which takes into account
both direct costs and indirect costs (such as lost participation
in workforce).10 This is an average cost per inhabitant of
around five and a half thousand euros. More specifically,
neuromuscular disorders (excluding multiple sclerosis and
Parkinson's) have an economic cost of around 7.7 billion EUR
and epilepsy (both adult and paediatric) has a cost of around
13.8 billion EUR.10 As we see further on in this section, such
economic considerations are increasingly shaping health and
research policies in the EU. Together, the economic implica-
tions and unmet clinical need necessitate urgent research
into, and development of, neuromodulation therapies, and
thus provide an important moral justification for advancing
the field of paediatric neuromodulation as a whole.
This great need has of course attracted considerable com-
mercial interest, and some therapeutic areas in the field now
represent lucrative markets for device manufacturers; this is
another important aspect of the social context of neuro-
modulation. In 2014, the total net sales of neuromodulation
technology of the top three manufacturers (Medtronic, Boston
Scientific, and St Jude Medical) was just under three billion
USD, and generally the field is characterised by a high rate of
innovation.11 One reason manufacturers have been so inter-
ested in the field is that the same technology platform can be
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adapted into multiple disease areas e this is particularly the
case with deep brain stimulation,12 which has seen the recent
dissemination of DBS technique into various psychiatric dis-
orders. Neuromodulation typically entails complex, high-
performance technology, and the regulatory burden in some
therapeutic applications is high; the field, then, is dependent
on industrial partners with sufficient technical and regulatory
expertise and with the financial resources required to gain
market access. Indeed, historically, neuromodulation (as with
developments in medicine more generally) owes its existence
to key clinician-industry partnerships, and manufacturers
have been instrumental in facilitating the dissemination of
the technology into new disease areas.13 The dependence on
industry need not be seen negatively, but some commentators
have argued that the considerable commercial interests
within the area necessitate that investigators and clinicians
maintain a degree of vigilance.14 Corporatemotivations could,
it has been suggested, unnecessarily put patients at risk, and
specific concerns have been raised in the US regarding a
manufacturer's supposed ‘misuse’ of a regulatory exemption
in DBS for adult obsessive compulsive disorder.15 Such senti-
ment no doubt reflects a more general distrust of large in-
dustry involvement in healthcare that has been stoked by past
scandals in the domain of pharmaceuticals, but regardless as
to whether such sentiment is justified, it is expedient for in-
vestigatorswithin the field of neuromodulation to be aware of,
and reflect upon, the influence of commercial interests. More
specifically, it is wise for investigators in paediatric neuro-
modulation to adopt an approach to clinical research that
ensures that commercial interests align with those of the
patient, and that the latter are not ignored in the pursuit of
lucrative markets.
Funding pressures represent another key aspect of the
social context of neuromodulation. Rising healthcare costs,
driven partly by the introduction and dissemination of high-
cost technologies, is a major concern for governments.
Healthcare budgets are under increasing strain, and there is
considerable political pressure to cut costs and find effi-
ciencies within healthcare systems. In the UK, for example,
the NHS is said to be heading towards the equivalent of a 40
billion EUR funding gap by 2021.16 One consequence of this is
that commissioning authorities are increasingly relying on
formal technology appraisals when making decisions as to
whether a newmedical therapy will be implemented within a
healthcare system. Within the EU, initiatives have been
launched to encouraging a convergence towards the adoption
of health technology assessment (HTA) standards for medical
devices: the EU Commission-funded MedtechHTA project, for
example, aims to identify appropriate HTA methodologies,
and to encourage greater harmonisation among the HTA au-
thorities of member states.17
This means that it is becoming increasingly important to
demonstrate the cost effectiveness and clinical effectiveness
of new device-based therapies. The general purpose of anHTA
is to determine: to what degree does the therapy benefit the
patient? What is the cost of delivering this benefit to all those
in the proposed patient group? What are the wider social
benefits of the therapy? And in some cases: how does the
benefit/cost compare to existing standards of care? Currently
the ways in which these questions are addressed can vary
greatly from one HTA authority to another, but in most cases
the data required to do so is much broader in nature than that
which is required to obtain regulatory approval. The deter-
mination of patient benefit (or clinical effectiveness), for
example, may require a broad array of data (both quantitative
and qualitative) on the impact of the therapy in the patient's
day-to-day life, and the calculation of ‘cost effectiveness’ can
entail a variety of data including the direct costs (setting-up
supporting infrastructure, training staff, etc), and indirect
costs (such as those resulting from changes in work produc-
tivity and social care). Manufacturers and investigators are
thus expected to design clinical studies in such a way that this
various data can be collected.
The relevance of HTA to the field of paediatric neuro-
stimulation will obviously differ depending on the specific
application. Low cost devices, or devices used in clinical
studies or in ‘one-off’ treatments, will continue to be
commissioned at a regional level by hospital authorities.
However, therapies that are perceived to have high-up front
costs or a significant target population, are more likely to be
subject to formal HTA. Manufacturers will be expected to
clearly demonstrate the cost implications and the clinical
benefits compared to existing standards of care. In other fields
such as regenerative medicine, HTA has been labelled amajor
hurdle to clinical adoption, and manufacturers are being
encouraged to cater their product development pathways
accordingly as early as possible.18
Public perception, particularly hype and high expectation,
is another important aspect of the neuromodulation social
context that needs to be considered. It is not unusual for news
media to propagate highly optimistic and potentially
misleading representations of biomedical advancements,
using terms such as ‘breakthrough’, ‘life-changing’, and ‘rev-
olutionary’.19 Much social science work has explored the
consequences of this.20,21 On the one hand, such optimism
provides biomedical projects with much needed momentum
e it helps attract and consolidate the attention, resources and
investment necessary for further development. On the other
hand, optimistic portrayals can exacerbate distrust and
scepticism among the public, especially when projects fail to
deliver on their promise.
Hype and high expectation has surrounded developments
in neuromodulation, particularly deep brain stimulation.
Several studies have exploredmedia coverage of DBS for adult
movement disorders, noting that it has been ‘overly opti-
mistic’ and has tended to focus on those individual cases that
do dramatically well, thus giving the impression that all pa-
tients will respond in this way.22,23 Clinicians working within
DBS paediatric services have reported that families often
arrive with unrealistic expectations, and that managing these
expectations entails considerable work.24 Such work is a
necessary aspect of the informed consent process, but it is
also necessary for protecting the reputation of the service and
the therapy itself. Clinicians have felt that if family expecta-
tions are not sufficientlymanaged and families (who are often
active in social media) feel mislead, they are “setting their
service up for certain failure”.24 It is important, then, that
clinicians careful scrutinize the expectations of patients and
their families, and communicate the likely benefits of neuro-
modulation therapies using accessible terms and frames of
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reference. This is of course particularly important in highly
invasive procedures such as DBS.
It is partly in response to these tensions surrounding
biomedical innovation (and science and innovation more
broadly) that the European Commission launched its
Responsible Research and Innovation (RRI) initiative.25 The
motivation for RRI has been a perception among European
policy makers that existing policy is inadequate for guiding
innovation in emerging, potentially ethically problematic
areas of science and technology.26 The initiative is still very
much in its infancy, and the details of what exactly qualifies
as ‘responsible’ have not been clearly delineated, but the
overall purpose of the initiative is to encourage research and
innovation that addresses the needs of European citizens in a
manner that accords with European values. Advocates argue
that research and innovation projects need to be responsive to
the input of a range of stakeholders who can represent and
identify the needs of citizens25: greater public engagement
that broadens input beyond commercial and professional in-
terests can help ensure that innovation is better directed to-
wards genuine social need.
The RRI initiative is intended to guide the formation of
national and European-level policy. Exactly what impact it
will have it is not clear, but it is likely that funders and other
influential bodies will expect investigators to demonstrate
sensitivity to the core elements of RRI. Indeed, the Nuffield
Council on Bioethics has adopted the initiative into their
ethical framework for developing novel neurotechnologies9:
They argue that RRI in the context of neurotechnology (within
which they include neuromodulation) would entail the gen-
eration of robust evidence on safety and efficacy, constant
reflexive evaluation of the specific technology, and the input
of multiple stakeholder perspectives.27 RRI represents a sig-
nificant and potentially influential discourse in the social
context of paediatric neuromodulation, and indeed, biomed-
icine more generally. It is important, then, that activities of
investigators and clinicians within the field reflect an aware-
ness of the initiative.
The following section will introduce a means by which
clinicians working within paediatric neuromodulation can
both adhere to RRI and navigate the other challenges outlined
above. This is to adopt what will be described as a broad clinical
gaze. In general terms the broad clinical gaze is a particular
attitude to clinical work, but as Section 3 will suggest, there
are specific means by which the broad clinical gaze can be
operationalised in clinical practice.
3. The broad clinical gaze: enacting
responsible research and innovation
The tensions and challenges outlined above have set forth a
set of requirements for clinicians and investigators working
within emerging areas of biomedicine such as paediatric
neuromodulation. First, it is becoming increasingly impor-
tant to ensure that the viewpoints of citizens are incorpo-
rated into the design of clinical studies and the design of
clinical services providing novel treatments. Generally, this
means the viewpoints of patient association and advocacy
groups. Second, clinical studies and clinical services
providing novel therapies, particularly those that are high
cost, need to generate data that can be used to calculate cost
effectiveness. And third, clinical studies and services also
need to be able to generate data on the benefits of a therapy.
This includes data on the day-to-day social impact of the
therapy for the child and their family, which is wider in scope
than that which is generally used to demonstrate clinical
‘efficacy’. If clinicians and investigators are able to suffi-
ciently satisfy each of these requirements, then it will be
possible to objectively elucidate the true benefit of neuro-
modulation using criteria that align with the values and
perspectives of those who will be most affected by it. To do
this, I propose that it is expedient for clinicians and in-
vestigators to adopt a broad clinical gaze. In order to explain
precisely what this is and how it can be operationalised in
clinical practice, it is necessary to briefly introduce the
concept of the medical gaze, as it has been characterised by
the highly influential French philosopher Michel Foucault.28
The medical gaze, Foucault argued, is a particular way of
perceiving disease and the body that emerged in the early 19th
century, and which has since become the basis of modern
medicine. Prior to its emergence, diseasewas perceived to be a
phenomenon that affected the physical body, but ultimately
existed in an immaterial ‘spiritual’ realm. The emergence of
the medical gaze signalled a paradigm shift; a reconceptuali-
zation of disease as a material, physical phenomena e bio-
physiological processes e that could be understood through
close empirical investigation of the diseased-body.28 With this
change in perception medicine became a ‘true science’ and
flourished, and the patient's body became an invaluable
source of biomedical data. The emergence of themedical gaze
is thus associated with what has been referred to as the
biomedical model of disease.29 The positive impact of this
paradigm shift is immense and incalculable. Nevertheless it
did recast the clinicianepatient relationship in such a way
that it acquired, in some contexts, an ethically-problematic
paternalistic dynamic: The clinician's viewpoint, informed
by their expertise in reading biomedical signs and symptoms,
eclipsed that of the patient who experienced the disease, and
in some contexts this meant that patients had very little input
in decisions regarding their care.30 Since the 1970s advocates
of patient-centred medicine e which has influenced health-
care policy in many countries31 e have lobbied for greater
accommodation of patient viewpoints in healthcare practices,
and they have argued that disease should be perceived and
treated as a biopsychosocial phenomenon, rather than just a
biomedical one.32 It is within this line of thinking that the
notion of broad clinical gaze has its genesis: it is a broadening
of the medical gaze described by Foucault28 to include psy-
chological and social aspects of disease. It can therefore be
defined as:
A clinical interest that extends from the shapes and structures of
the body, to the emotional state of the patient, to elements of the
patient's social context and their ability to act within it.
Modern medicine, brought about by the emergence of the
medical gaze, has had an immeasurable impact on human
welfare. However, medical innovation in the current social
context increasingly necessitates that clinicians and
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investigators adopt a broader perspective of disease: a broad
clinical gaze, thus recognising that diseases have important
non-biomedical aspects which need to be accommodated in
the design of clinical studies and clinical services providing
novel therapies.
Given that the patient-centred medicine movement has
already influenced a great deal of clinical work in many con-
texts, the broad clinical gaze will not represent a stark de-
parture from howmany clinicians and investigators approach
their day-to-day work. This is especially true for those work-
ing in the field of paediatric neuromodulation: clinicians
working in paediatric settings have generally been concerned
with, and attentive to, the social impact of childhood chronic
illness, particularly the impact on family life. As a general
philosophy, then, the broad clinical gaze will align with cur-
rent, commonperspectives on how clinical research should be
conducted and how clinical services should be delivered:
indeed, in the following section I highlight some existing
practices and examples e some of which are reported in
greater depth in this special issue e of how the broad clinical
gaze can be operationalised in clinical work.
3.1. Operationalising the broad clinical gaze
One effectiveway of operationalising the broad clinical gaze in
clinical settings is via multidisciplinary and interdisciplinary
teamwork. Multi- and interdisciplinary teams contain a range
of professional viewpoints which can help provide a more
holistic understanding of the impact of disease upon a patient
and the impact of an intervention. The ideal composition of a
teamwill vary depending on the nature of the disease and the
intervention being offered. Small teams are suitable for
delivering routine, low risk (non- or minimally-invasive)
neuromodulation therapies, but invasive, high-cost thera-
pies such as DBS for movement disorders may be better
delivered by larger teams representing a range of professions
including allied health disciplines (physiotherapy, clinical
psychology, speech and language therapy), and ideally disci-
plines that place a heavy emphasis on patient-centred ap-
proaches (such as occupational therapy). The collective
expertise of such teams enable them to scrutinize and attend
to the biomedical, psychological and social (or domestic) as-
pects of neurological disease, and to examine how these
various dimensions are affected by neuromodulation. While
each member of a team will be working towards the same
broad goals (improving the well-being of patients and their
families), tensions may arise as team members draw on their
specific disciplinary-based understandings and values. Such
tension need not be seen negatively; indeed, it can prompt
teams to engage in reflexive evaluation e an important
component of RRI, according to the Nuffield Council on
Bioethics.9 It is important, however, that team members are
provided with regular opportunities to provide meaningful
input into discussions and clinical decision-making33: studies
of teams in other fields have noted that the potential benefits
of interdisciplinarity can been stunted by traditional hierar-
chies as doctors ewith their largely biomedical-based clinical
opinion e dominate clinical decision-making34
Another advantage of such teams is that allied health
professionals may have more opportunities to spend time
with families, perhaps as they conduct assessments. This can
facilitate trust and open communication, and families will be
more willing to speak openly and willingly about their chal-
lenges and their expectations. Indeed, multi & interdisci-
plinary teams are well-suited to managing the expectations of
patients and families. Drawing on discipline-specific exper-
tise, they can elucidate the hopes and expectations of families
and communicate anticipated clinical outcomes to families,
using frames of reference that patients and families can un-
derstand, such as an improved ability to perform specific ac-
tivities of daily living.24
Another way in which the broad clinical gaze can be
operationalised in neuromodulation is via the adoption of
patient-centred clinical assessment tools. Such tools, which
are commonplace in allied health disciplines (particularly
occupational therapy) can be used to capture clinical changes
that families themselves feel are important. Assessment tool
that capture and quantify the psychological and social impact
of disease can be used to complement the more conventional
impairment based tools commonly used in neurology. Some
examples include the Canadian Occupational Performance
Measure35 which measures patients' self-perceptions of their
abilities, and the Assessment of Motor and Process Skills36
which can be used to assess a patient's ability to perform
domestic tasks (‘activities of daily living’) that patients and
families would like to improve. Both tools can provide clini-
cians with a sense of how the disease and the intervention are
impacting day-to-day life. The importance of using such tools
as part of a broad assessment regime has been demonstrated
by clinicians working within a service providing DBS to young
patients with dystonia (Gimeno, this issue). These patient-
centred tools appear to capture important improvements
that impairment based measures (the Burke-Fahn-Marsden
Dystonia Rating Scale) are insensitive to, particularly among
patients with complex secondary dystonias.37 The data that
patient-centred tools produce support reflective evaluation of
the neuromodulation intervention, and they may be essential
for calculating cost and clinical effectiveness of the inter-
vention as part of a formal HTA.
Patient registries, such as the Dystonia DBS database
currently under construction and reported here in this issue,
are another means by which the broad clinical gaze can be
operationalized. Patient registries and databases can have a
variety of purposes (documenting the natural history of a
disease; providing an inventory of patients for clinical
research etc) but they can be a particularly useful tool for
capturing data on the impact of an intervention, especially in
contexts where larger scale clinical trials are not possible and
when the intervention is being offered in a few dispersed
centres.38,39 Depending on how a registry is designed, it can
capture data relating to the cost and social impact of an
intervention. It may, then, provide valuable evidence for
formal health technology appraisals40: the UK's National
Institute for Health and Care Excellence (NICE), for example,
has used data captured in registries for conducting cost
effectiveness evaluations in other fields.
A particularly important feature of registries and databases
is that they provide an opportunity for patient-involvement in
research design. Patient associations and affected families
can be consulted in the design of registries to ensure their
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concerns are reflected in the type of data that is collected.
Patient association groupsmay also be involved in the day-to-
day management of the registry.37 They can, then, serve as a
useful means of ensuring that the interests and values of
citizens are being attended to in neuromodulation research
and delivery, thus facilitating responsible research and inno-
vation within the field. The need for a database to capture the
impact of DBS in paediatric dystonias has been recognised by
clinicians in the field e in this issue, Marks reports on efforts
to produce a database that will pool together DBS outcomes
from several centres, and will thus serve as a useful body of
evidence on the effectiveness of DBS.
There are, of course, considerable challenges in establish-
ing patient registries and databases. They require constant
oversight and long-term funding. Care needs to be taken
during their design to ensure that the data they collect can
address key, well-defined objectives. Clinical centreswill need
to decide on a set of shared standards for collecting data for
the registry, and ideally, registries will be designed so that
additional, perhaps unanticipated concerns can be addressed
in the future. There is, then, a great deal of work and negoti-
ation involved in the establishment and maintenance of pa-
tient databases. Partly in recognition of these challenges, the
European Commission is co-funding actions to promote and
support the establishment of patient registries within EU
member countries.41
4. Conclusion: Institutionalising RRI within
paediatric neuromodulation
Here I have identified several ways in which the broad clinical
gaze can be e and indeed has been e operationalized in clin-
ical practice within the field of neuromodulation: Multidisci-
plinary teamwork, the adoption of patient-centred clinical
assessment tools, and the use of patient registries are useful
means by which clinicians working within neuromodulation
can navigate the tensions described above and align their field
with the tenets of responsible research and innovation. This
is, of course, easier said than done. Inevitably, institutional
constraints will hinder the ability to operationalise a broad
clinical gaze in clinical settings. In many contexts, institu-
tional funding pressures or rigid payment structures will
mean that it is not financially feasible to support a multidis-
ciplinary service containing the ideal range of health disci-
plines. Theremay be a reluctance to adopt clinical assessment
tools from the allied health disciplines because journal editors
and reviewerswithin neurologymay be unfamiliar with them,
preferring the use of ‘heritage’ impairment tools. Clinical
teams may be reluctant to place their arduously-collected
data on a shared registry or database, especially in a
competitive professional climate.
The specificmeans of operationalised the gaze outline here
e multidisciplinary teamwork, the adoption of patient-
centred assessment tools, and the use of patient registries e
will obviously not be appropriate for all areas of neuro-
modulation. It is important therefore that clinicians within
the field remain attentive to other potential ways of practicing
a broad clinical gaze, and other ways of adhering to the sen-
timents of responsible research and innovation. Are there, for
example, other ways in which the social impact of a neuro-
modulation therapy for children can be captured? Are there
other ways of engaging children, families and patient associ-
ations within research into neuromodulation, and in the
design of neuromodulation services? Operationalising a broad
clinical gaze within neuromodulation, therefore, will require
some degree of institutional change, and this in-turn will
require co-ordinated effort from those working within the
field. It is for this reason that a regular forum for those
working within the field, such as the recent EPNS satellite
symposium (May, 2015), is necessary: it provides an opportu-
nity for reflexive evaluation of the field as a whole, knowledge
sharing, and the coordination of effort across international
contexts. These activities are needed to ensure that the field
as a whole can responsibly and ethically deliver on its signif-
icant clinical potential to address the huge clinical need, and
they will, hopefully, mean that in forty years' time commen-
tators will not look back on this era of neuromodulation with
the same sense of frustration as we do when reflecting on the
work of Irving Cooper.
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